Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Cost of Revenue data on file, last reported at $12.0 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 222.13% year-over-year to $12.0 million in Q1 2026; TTM through Mar 2026 was $30.9 million, a 173.91% increase from a year earlier, with the FY2025 full-year figure at $22.6 million, up 183.44% from the prior year.
• Cost of Revenue for Q1 2026 stood at $12.0 million, up from $7.6 million in the prior quarter.
• Over the last five years, Cost of Revenue for PHAT reached as high as $12.0 million in Q1 2026 and fell as low as $167000.0 in Q4 2023.
• Historically, Cost of Revenue has averaged $4.3 million across 4 years, with a median of $3.8 million in 2024.
• Across the five-year window, Cost of Revenue surged 2184.43% in 2024 and surged 100.47% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $167000.0 in 2023, then jumped by 2184.43% to $3.8 million in 2024, then soared by 100.47% to $7.6 million in 2025, then soared by 56.85% to $12.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $12.0 million in Q1 2026, $7.6 million in Q4 2025, and $6.2 million in Q3 2025.